Saniona and Medix sign development and commercialisation agreement for tesofensine and Tesomet in Mexico and Argentina

Saniona, a leading biotech company in the field of ion channels, today announces that it has entered into a drug development and commercialisation collaboration with Productos Medix, S.A de S.V (Medix). Medix is granted exclusive rights to develop and commercialise tesofensine and Tesomet in Mexico and Argentina. Medix will finance and be responsible for the clinical development and regulatory filings in the two countries. Medix intends to initiate Phase 3 clinical studies for tesofensine for obesity later this year. Saniona retains all rights to tesofensine and Tesomet in the rest of the world. Medix will pay Saniona an upfront payment of US$ 1.25 million (about SEK 10.5 million), regulatory milestone payments, and double-digit royalties on product sales.

The release as fetched from its publisher. saniona.com ↗